Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 404

1.

Persistent/Recurrent Differentiated Thyroid Cancer: Clinical and Radiological Characteristics of Persistent Disease and Clinical Recurrence Based on Computed Tomography Analysis.

Kim TM, Kim JH, Yoo RE, Kim SC, Chung EJ, Hong EK, Jo SW, Kang KM, Choi SH, Sohn CH, Rhim JH, Park SW, Park YJ.

Thyroid. 2018 Sep 18. doi: 10.1089/thy.2018.0151. [Epub ahead of print]

PMID:
30226443
2.

Renal Ischemia-Reperfusion Injury in a Diabetic Monkey Model and Therapeutic Testing of Human Bone Marrow-Derived Mesenchymal Stem Cells.

Lee KW, Kim TM, Kim KS, Lee S, Cho J, Park JB, Kwon GY, Kim SJ.

J Diabetes Res. 2018 Aug 1;2018:5182606. doi: 10.1155/2018/5182606. eCollection 2018.

3.

Mutation heterogeneity between primary gastric cancers and their matched lymph node metastases.

Lee HH, Kim SY, Jung ES, Yoo J, Kim TM.

Gastric Cancer. 2018 Aug 21. doi: 10.1007/s10120-018-0870-6. [Epub ahead of print]

PMID:
30132154
4.

Effect of Smoking on Healing Failure After Rotator Cuff Repair.

Park JH, Oh KS, Kim TM, Kim J, Yoon JP, Kim JY, Chung SW.

Am J Sports Med. 2018 Aug 21:363546518789691. doi: 10.1177/0363546518789691. [Epub ahead of print]

PMID:
30129777
5.

Effect of sorghum ethyl-acetate extract on benign prostatic hyperplasia induced by testosterone in Sprague-Dawley rats.

Ryu JM, Jang GY, Park D, Woo KS, Kim TM, Jeong HS, Kim DJ.

Biosci Biotechnol Biochem. 2018 Aug 18:1-8. doi: 10.1080/09168451.2018.1507721. [Epub ahead of print]

PMID:
30124113
6.

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity.

Yoo SH, Keam B, Kim M, Kim SH, Kim YJ, Kim TM, Kim DW, Lee JS, Heo DS.

ESMO Open. 2018 Jul 25;3(5):e000332. doi: 10.1136/esmoopen-2018-000332. eCollection 2018.

7.

Clinical experiences and case review of angiotensin II receptor blocker-related angioedema in Korea.

Kim H, Baik SY, Yang SJ, Kim TM, Lee SH, Cho JH, Choi IY, Kim JH, Yoon KH, Kim HS.

Basic Clin Pharmacol Toxicol. 2018 Jul 13. doi: 10.1111/bcpt.13097. [Epub ahead of print]

PMID:
30003686
8.

Identification of local clusters of mutation hotspots in cancer-related genes and their biological relevance.

Rhee JK, Yoo J, Kim KR, Kim J, Lee YJ, Cho BC, Kim TM.

IEEE/ACM Trans Comput Biol Bioinform. 2018 Mar 16. doi: 10.1109/TCBB.2018.2813375. [Epub ahead of print]

PMID:
29993813
9.

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS.

Korean J Intern Med. 2018 Jun 29. doi: 10.3904/kjim.2018.011. [Epub ahead of print]

10.

Survival gain with re-Op/RT for recurred high-grade gliomas depends upon risk groups.

Chun SJ, Park SH, Park CK, Kim JW, Kim TM, Choi SH, Lee ST, Kim IH.

Radiother Oncol. 2018 Aug;128(2):254-259. doi: 10.1016/j.radonc.2018.05.024. Epub 2018 Jun 21.

PMID:
29937212
11.

Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system.

Nam SJ, Kim S, Kwon D, Kim H, Kim S, Lee E, Kim TM, Heo DS, Park SH, Lim MS, Kim CW, Jeon YK.

Oncoimmunology. 2018 Mar 13;7(7):e1442164. doi: 10.1080/2162402X.2018.1442164. eCollection 2018.

12.

Prevalence and Predictors of Patellofemoral Osteoarthritis after Anterior Cruciate Ligament Reconstruction with Hamstring Tendon Autograft.

Lee DW, Yeom CH, Kim DH, Kim TM, Kim JG.

Clin Orthop Surg. 2018 Jun;10(2):181-190. doi: 10.4055/cios.2018.10.2.181. Epub 2018 May 18.

13.

Improvement of Trehalose Production by Immobilized Trehalose Synthase from Thermus thermophilus HB27.

Sun J, Wang S, Li W, Li R, Chen S, Ri HI, Kim TM, Kang MS, Sun L, Sun X, Yuan Q.

Molecules. 2018 May 4;23(5). pii: E1087. doi: 10.3390/molecules23051087.

14.

Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma.

Hong EK, Choi SH, Shin DJ, Jo SW, Yoo RE, Kang KM, Yun TJ, Kim JH, Sohn CH, Park SH, Won JK, Kim TM, Park CK, Kim IH, Lee ST.

Eur Radiol. 2018 Oct;28(10):4350-4361. doi: 10.1007/s00330-018-5400-8. Epub 2018 May 2.

PMID:
29721688
15.

Population-based statistical inference for temporal sequence of somatic mutations in cancer genomes.

Rhee JK, Kim TM.

BMC Med Genomics. 2018 Apr 20;11(Suppl 2):29. doi: 10.1186/s12920-018-0352-z.

16.

Refractory patellar tendinopathy treated by arthroscopic decortication of the inferior patellar pole in athletes: Mid-term outcomes.

Lee DW, Kim JG, Kim TM, Kim DH.

Knee. 2018 Jun;25(3):499-506. doi: 10.1016/j.knee.2018.02.015. Epub 2018 Apr 21.

PMID:
29685503
17.

Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.

Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS.

Thorac Cancer. 2018 Jun;9(6):736-744. doi: 10.1111/1759-7714.12641. Epub 2018 Apr 22.

PMID:
29682899
18.

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.

Zhang W, McIntyre C, Kuhn M, Forbes H, Kim TM, Lee J, Demidov L, Colburn D.

J Clin Pharmacol. 2018 Apr 12. doi: 10.1002/jcph.1111. [Epub ahead of print]

PMID:
29645280
19.

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy.

Choi JY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Jo SJ.

Cancer Res Treat. 2018 Apr 5. doi: 10.4143/crt.2017.491. [Epub ahead of print]

20.

CD21-independent Epstein-Barr virus entry into NK cells.

Lee JH, Choi J, Ahn YO, Kim TM, Heo DS.

Cell Immunol. 2018 May;327:21-25. doi: 10.1016/j.cellimm.2018.01.011. Epub 2018 Jan 17.

PMID:
29499908
21.

Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance.

Suh KJ, Kim KH, Kim R, Byun JM, Kim M, Park JH, Keam B, Kim TM, Kim JS, Choi IS, Heo DS.

Korean J Intern Med. 2018 Feb 23. doi: 10.3904/kjim.2017.174. [Epub ahead of print]

22.

Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice.

Kim H, Lee H, Kim TM, Yang SJ, Baik SY, Lee SH, Cho JH, Lee H, Yim HW, Choi IY, Yoon KH, Kim HS.

Cardiovasc Ther. 2018 Jun;36(3):e12324. doi: 10.1111/1755-5922.12324. Epub 2018 Mar 6.

PMID:
29464863
23.

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.

Jo J, Kim SH, Kim YJ, Lee J, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Chung JH, Jeon YK, Lee JS.

Yonsei Med J. 2018 Mar;59(2):202-210. doi: 10.3349/ymj.2018.59.2.202.

24.

Therapeutic effects of anti-CD154 antibody in cynomolgus monkeys with advanced rheumatoid arthritis.

Choi EW, Lee KW, Park H, Kim H, Lee JH, Song JW, Yang J, Kwon Y, Kim TM, Park JB, Kim S.

Sci Rep. 2018 Feb 1;8(1):2135. doi: 10.1038/s41598-018-20566-z.

25.

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ.

Ann Oncol. 2018 Jan 29. doi: 10.1093/annonc/mdx807. [Epub ahead of print] No abstract available.

PMID:
29390043
26.

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.

Park S, Ha S, Lee SH, Paeng JC, Keam B, Kim TM, Kim DW, Heo DS.

PLoS One. 2018 Jan 31;13(1):e0189766. doi: 10.1371/journal.pone.0189766. eCollection 2018.

27.

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.

Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM.

Am J Hematol. 2018 May;93(5):607-614. doi: 10.1002/ajh.25043. Epub 2018 Feb 8.

28.

Leakage correction improves prognosis prediction of dynamic susceptibility contrast perfusion MRI in primary central nervous system lymphoma.

Kim YS, Choi SH, Yoo RE, Kang KM, Yun TJ, Kim JH, Sohn CH, Park SH, Won JK, Kim TM, Park CK, Kim IH.

Sci Rep. 2018 Jan 11;8(1):456. doi: 10.1038/s41598-017-18901-x.

29.

Magnetic Nanowire Networks for Dual-Isolation and Detection of Tumor-Associated Circulating Biomarkers.

Lee H, Choi M, Lim J, Jo M, Han JY, Kim TM, Cho Y.

Theranostics. 2018 Jan 1;8(2):505-517. doi: 10.7150/thno.21967. eCollection 2018.

30.

Differentiation of High-Grade from Low-Grade Astrocytoma: Improvement in Diagnostic Accuracy and Reliability of Pharmacokinetic Parameters from DCE MR Imaging by Using Arterial Input Functions Obtained from DSC MR Imaging.

You SH, Choi SH, Kim TM, Park CK, Park SH, Won JK, Kim IH, Lee ST, Choi HJ, Yoo RE, Kang KM, Yun TJ, Kim JH, Sohn CH.

Radiology. 2018 Mar;286(3):981-991. doi: 10.1148/radiol.2017170764. Epub 2017 Dec 15.

PMID:
29244617
31.

The association between the nicotinic acetylcholine receptor α4 subunit gene (CHRNA4) rs1044396 and Internet gaming disorder in Korean male adults.

Jeong JE, Rhee JK, Kim TM, Kwak SM, Bang SH, Cho H, Cheon YH, Min JA, Yoo GS, Kim K, Choi JS, Choi SW, Kim DJ.

PLoS One. 2017 Dec 14;12(12):e0188358. doi: 10.1371/journal.pone.0188358. eCollection 2017.

32.

The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study.

Lee J, Lim J, Park JS, Kim M, Kim TY, Kim TM, Lee KH, Keam B, Han SW, Mun JH, Cho KH, Jo SJ.

Cancer Res Treat. 2017 Dec 14. doi: 10.4143/crt.2017.435. [Epub ahead of print]

33.

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.

Ock CY, Kim S, Keam B, Kim S, Ahn YO, Chung EJ, Kim JH, Kim TM, Kwon SK, Jeon YK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS.

Oncotarget. 2017 Jun 16;8(58):97920-97927. doi: 10.18632/oncotarget.18542. eCollection 2017 Nov 17.

34.

Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.

Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS.

Cancer Immunol Immunother. 2018 Mar;67(3):459-470. doi: 10.1007/s00262-017-2092-x. Epub 2017 Dec 4.

PMID:
29204702
35.

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.

Cho KM, Keam B, Ha H, Kim M, Jung JW, Song WJ, Kim TM, Jeon YK, Kang HR, Kim DW, Kim CW, Heo DS.

Korean J Intern Med. 2017 Nov 20. doi: 10.3904/kjim.2017.036. [Epub ahead of print]

36.

Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types.

Rhee JK, Jung YC, Kim KR, Yoo J, Kim J, Lee YJ, Ko YH, Lee HH, Cho BC, Kim TM.

Cancer Immunol Res. 2018 Jan;6(1):87-97. doi: 10.1158/2326-6066.CIR-17-0201. Epub 2017 Nov 15.

PMID:
29141981
37.

Passage-dependent accumulation of somatic mutations in mesenchymal stromal cells during in vitro culture revealed by whole genome sequencing.

Kim M, Rhee JK, Choi H, Kwon A, Kim J, Lee GD, Jekarl DW, Lee S, Kim Y, Kim TM.

Sci Rep. 2017 Nov 6;7(1):14508. doi: 10.1038/s41598-017-15155-5.

38.

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.

Shitara K, Kim TM, Yokota T, Goto M, Satoh T, Ahn JH, Kim HS, Assadourian S, Gomez C, Harnois M, Hamauchi S, Kudo T, Doi T, Bang YJ.

Oncotarget. 2017 Jun 16;8(45):79546-79555. doi: 10.18632/oncotarget.18554. eCollection 2017 Oct 3.

39.

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.

Kim H, Park CM, Keam B, Park SJ, Kim M, Kim TM, Kim DW, Heo DS, Goo JM.

PLoS One. 2017 Nov 3;12(11):e0187500. doi: 10.1371/journal.pone.0187500. eCollection 2017.

40.

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC.

Lancet Respir Med. 2017 Nov;5(11):891-902. doi: 10.1016/S2213-2600(17)30378-8. Epub 2017 Oct 19.

PMID:
29056570
41.

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.

Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS.

Nat Commun. 2017 Oct 19;8(1):1050. doi: 10.1038/s41467-017-01018-0.

42.

Epstein-Barr Virus-Associated Vesiculopapular Eruption on the Face of a Patient with Natural Killer T Cell Lymphoma.

Lim JS, Kim TM, Cho KH.

Ann Dermatol. 2017 Oct;29(5):618-620. doi: 10.5021/ad.2017.29.5.618. Epub 2017 Aug 25.

43.

Role of radiation therapy in primary central nervous system lymphoma : KROG 14-20 Collaborative Study of Brain and Lymphoma Committee.

Koh HK, Kim IH, Kim TM, Lim DH, Oh D, Cho JH, Kim WC, Kim JH, Chung WK, Jeong BK, Kang KM, Hong S, Suh CO, Kim IA.

J Neurooncol. 2017 Dec;135(3):629-638. doi: 10.1007/s11060-017-2616-4. Epub 2017 Sep 22.

PMID:
28939931
44.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators.

N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.

45.

Recursive partitioning analysis for disease progression in adult intracranial ependymoma patients.

Song SW, Dho YS, Kim JW, Kim YH, Paek SH, Kim DG, Jung HW, Park SH, Choi SH, Kim TM, Lee ST, Kim IH, Lee SH, Park CK.

J Clin Neurosci. 2017 Dec;46:72-78. doi: 10.1016/j.jocn.2017.08.056. Epub 2017 Sep 8.

PMID:
28890044
46.

Erratum to: Loss of Pericytes in Radiation Necrosis after Glioblastoma Treatments.

Lee ST, Seo Y, Bae JY, Chu K, Kim JW, Choi SH, Kim TM, Kim IH, Park SH, Park CK.

Mol Neurobiol. 2018 Jun;55(6):4927. doi: 10.1007/s12035-017-0765-2. No abstract available.

PMID:
28889334
47.

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.

Kim TM, Lee KW, Oh DY, Lee JS, Im SA, Kim DW, Han SW, Kim YJ, Kim TY, Kim JH, Han H, Kim WH, Bang YJ.

Cancer Res Treat. 2018 Jul;50(3):835-842. doi: 10.4143/crt.2017.303. Epub 2017 Aug 29.

48.

A Simple Way to Eradicate Methicillin-Resistant Staphylococcus aureus in Cynomolgus Macaques (Macaca fascicularis).

Kim TM, Park H, Lee KW, Choi EW, Moon SH, Lee YS, Cho K, Park WJ, Park JB, Kim SJ.

Comp Med. 2017 Aug 1;67(4):356-359.

49.

Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection.

Kim H, Chae KJ, Yoon SH, Kim M, Keam B, Kim TM, Kim DW, Goo JM, Park CM.

Eur Radiol. 2018 Feb;28(2):861-868. doi: 10.1007/s00330-017-5006-6. Epub 2017 Aug 7.

PMID:
28786010
50.

Loss of Pericytes in Radiation Necrosis after Glioblastoma Treatments.

Lee ST, Seo Y, Bae JY, Chu K, Kim JW, Choi SH, Kim TM, Kim IH, Park SH, Park CK.

Mol Neurobiol. 2018 Jun;55(6):4918-4926. doi: 10.1007/s12035-017-0695-z. Epub 2017 Aug 2. Erratum in: Mol Neurobiol. 2017 Sep 9;:.

PMID:
28770500

Supplemental Content

Support Center